927
Pipeline Therapeutics, a biopharmaceutical company focused on recovering brain function via neural regeneration, just raised $80 million in a Series C. The team plans to use the funds to advance their technology focusing on sensorineural hearing loss and another focused on multiple sclerosis.
Read more here.
